Induction of cyclo-oxygenase-2 expression in naturally occurring gastric ulcers

被引:6
|
作者
Lajoie, S
Sirois, J
Doré, M
机构
[1] Univ Montreal, Fac Med Vet, Dept Pathol & Microbiol, St Hyacinthe, PQ J2S 7C6, Canada
[2] Univ Montreal, Fac Med Vet, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada
关键词
cyclo-oxygenase-2; gastric ulcers; pigs; stomach;
D O I
10.1177/002215540205000706
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cyclo-oxygenase-2 (COX-2) is believed to participate in the repair of gastric ulcer. Like humans, pigs frequently develop gastric ulcers and thus represent an attractive animal model in which to study the repair process of naturally occurring gastric ulcers. However, expression of COX in the pig stomach has not been reported. The objectives of this study were to determine whether COX isoenzymes are expressed in porcine gastric ulcers and to characterize the porcine COX-2 cDNA. Normal stomachs (n=5) and those with gastric ulcers (n=35) were studied by immunohistochemistry and immunoblotting analysis. Reverse transcription-polymerase chain reaction (RT-PCR) was used to isolate the complete porcine COX-2 cDNA. COX-1 staining was present in normal stomach and in ulcerated areas. No COX-2 was detected in normal stomach, but COX-2 was strongly expressed in the ulcerated area in 28/35 (80%) gastric ulcers (p<0.01). Immunoblotting analysis confirmed the restricted expression of COX-2 in the ulcerated areas. The porcine COX-2 cDNA was shown to code for a 604 amino acid protein that is 89% identical to human COX-2. These results provide the complete primary structure of porcine COX-2 and demonstrate for the first time that the enzyme is induced in naturally occurring porcine gastric ulcers.
引用
收藏
页码:923 / 933
页数:11
相关论文
共 50 条
  • [41] Induction of cyclo-oxygenase-2 by acute liver allograft rejection and cytomegalovirus infection in the rat
    Martelius, TJ
    Wolff, H
    Bruggeman, CA
    Höckerstedt, KA
    Lautenschlager, IT
    TRANSPLANT INTERNATIONAL, 2002, 15 (12) : 610 - 614
  • [42] Pharmacokinetics of RofecoxibA Specific Cyclo-Oxygenase-2 Inhibitor
    Neal M. Davies
    Xiao W. Teng
    Neil M. Skjodt
    Clinical Pharmacokinetics, 2003, 42 : 545 - 556
  • [43] Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology
    Monsuez, JJ
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 2004, 97 (06): : 632 - 640
  • [44] Cardiovascular risks from inhibitors to cyclo-oxygenase-2
    Letonturier, P
    PRESSE MEDICALE, 2005, 34 (07): : 548 - 548
  • [45] Cyclo-Oxygenase-2 InhibitorsWhen Should They Be Used in the Elderly?
    Ruth Savage
    Drugs & Aging, 2005, 22 : 185 - 200
  • [46] Cyclo-oxygenase-2 and its inhibition in cancer - Is there a role?
    Liao, Zhonxing
    Mason, Kathryn A.
    Milas, Luka
    DRUGS, 2007, 67 (06) : 821 - 845
  • [47] Cyclo-oxygenase-2 in vascular smooth muscle (Review)
    Bishop-Bailey, D
    Hla, T
    Mitchell, JA
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 1999, 3 (01) : 41 - 48
  • [48] Pharmacokinetics of rofecoxib - A specific cyclo-oxygenase-2 inhibitor
    Davies, NM
    Teng, XW
    Skjodt, NM
    CLINICAL PHARMACOKINETICS, 2003, 42 (06) : 545 - 556
  • [49] Cyclo-oxygenase-2 inhibitors and COPD: a bright spot?
    Effros, RM
    Casaburi, R
    THORAX, 2005, 60 (10) : 796 - 796
  • [50] Cyclo-Oxygenase-2 and its Inhibition in CancerIs There a Role?
    Zhongxing Liao
    Kathryn A. Mason
    Luka Milas
    Drugs, 2007, 67 : 821 - 845